Micah Steffek
Tetra Therapeutics (United States)(US)
Publications by Year
Research Areas
RNA and protein synthesis mechanisms, Complement system in diseases, Cytokine Signaling Pathways and Interactions, Monoclonal and Polyclonal Antibodies Research, Myeloproliferative Neoplasms: Diagnosis and Treatment
Most-Cited Works
- → Structure of C3b in complex with CRIg gives insights into regulation of complement activation(2006)241 cited
- → Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab(2020)191 cited
- → An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance(2023)174 cited
- → Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling(2020)169 cited
- → ATP-Dependent l-Cysteine:1d-myo-Inosityl 2-Amino-2-deoxy-α-d-glucopyranoside Ligase, Mycothiol Biosynthesis Enzyme MshC, Is Related to Class I Cysteinyl-tRNA Synthetases(2002)101 cited
- → Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization(2020)101 cited
- → A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis(2007)96 cited
- → Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors(2012)92 cited
- → Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design(2013)67 cited
- → Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes(2024)67 cited